Aim: To share our experience in eyes with severe DME (exhibiting serous retinal detachment or large cysts) treated with simultaneous intravitreal ranibizumab and dexamethasone implant administration at the same setting as the first treatment step. Subjects and Results: Five eyes of three patients with DME who were either treatment naive or relatively undertreated were presented in this report. ...

OBJECTIVE To report our experiences in changing from intravitreal bevacizumab to ranibizumab in age-related macular degeneration (AMD). DESIGN Retrospective case series. PARTICIPANTS AND METHODS We retrospectively reviewed the records of 34 patients (36 eyes) who were treated with monthly injections of intravitreal bevacizumab for six months and then switched to monthly injections of ranibi...

AIM The aim of this article is to evaluate the rate of patients developing sustained elevated intraocular pressure (IOP) after ranibizumab (Lucentis) intravitreal (IVT) injections. DESIGN This is a retrospective study. PARTICIPANTS Charts of 192 consecutive patients receiving Lucentis for age-related macular degeneration (AMD) were retrospectively reviewed. MATERIALS AND METHODS We enroll...

OBJECTIVE To compare outcomes after switching from intravitreal ranibizumab to bevacizumab in neovascular age-related macular degeneration (AMD). METHODS A retrospective review of 110 eyes treated in a 1+PRN (pro re nata) clinical setting with ranibizumab that were switched to bevacizumab. Patients analyzed had at least 3 ranibizumab injections followed by at least 3 bevacizumab injections. C...

Aim. To assess the significance of age, gender, baseline best corrected visual acuity, baseline macula thickness, and type and size of choroidal neovascularization in early morphological therapeutic response to ranibizumab treatment in patients with the wet form of age-related macular degeneration. Methods. From 09/2008 to 06/2013 we evaluated 1153 newly diagnosed, treatment-naïve patients trea...

PURPOSE To compare therapeutic responses to intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration (AMD)-affected eyes with and without choroidal vascular hyperpermeability (CVH). METHODS Medical records of 216 consecutive patients (216 eyes) with treatment-naïve exudative AMD who had received three monthly intravitreal injections of aflibercept (2 mg) and ra...

OBJECTIVE To evaluate the efficacy of intravitreal Ranibizumab as treatment for choroidal neovascularisation due to pathological myopia. MATERIALS AND METHODS A retrospective, non-comparative study of 18 eyes treated with intravitreal injections of Ranibizumab. Ten eyes had been treated previously with photodynamic therapy and eight received Ranibizumab as first therapy. After thorough ophtha...

BACKGROUND To compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice. METHODS This was a retrospective study. Among 62 Chinese patients with DME, 32 patients (36 eyes) received intravitreal conbercept (IVC) injections and 30 patients (32 eyes) received intravitreal ranibizumab (IVR) injections, once a m...

AIMS To investigate the prognostic significance of macular capillary drop-out and previous panretinal laser photocoagulation in diabetic macular oedema treated with intravitreal ranibizumab. METHODS Retrospective observational case series. Treatment-naive patients with diabetic macular oedema that had been treated with intravitreal ranibizumab as per the RESTORE study protocol for at least 12...

The battle between two anti-vascular endothelial growth factor (VEGF) treatment options (ranibizumab and bevacizumab) for neovascular macular degeneration is a topic of particular significance to eye health professionals with an interest in cost-effective treatment. Being the first of its kind directly comparing the two anti-VEGF, a recent large multicentre clinical trial has shown that bevaciz...